Moxifloxacin Anfarm

Moxifloxacin, the active ingredient in Moxifloxacin Anfarm, is a fluoroquinolone antibiotic presented as an injectable solution for intravenous use. It is indicated for the treatment of severe community‑acquired pneumonia, complicated intra‑abdominal infections, and other serious bacterial infections requiring hospital‑based IV therapy.

GNH USA supplies Moxifloxacin Anfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Moxifloxacin is a fluoroquinolone antibiotic used to treat serious bacterial infections of the respiratory and abdominal systems. - Severe community‑acquired pneumonia: rapid bacterial eradication leading to clinical improvement in hospitalized patients. - Complicated intra‑abdominal infections: effective coverage of Gram‑negative, Gram‑positive and anaerobic pathogens in intra‑abdominal sepsis. - Hospital‑acquired bacterial infections: provides broad‑spectrum activity for severe infections requiring intravenous therapy.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Injection site reactions: erythema or pain at the infusion site. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially in the Achilles tendon. - QT interval prolongation: risk of cardiac arrhythmias, particularly in patients with pre‑existing heart disease. - Severe hypersensitivity: including anaphylaxis, rash, or angioedema. - Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions. - Hepatotoxicity: rare cases of liver injury.

When using Moxifloxacin Anfarm, clinicians should consider several safety precautions. - Renal impairment: adjust therapy based on clinical judgement and monitor renal function. - Hepatic dysfunction: monitor liver enzymes regularly during treatment. - QT prolongation risk: avoid in patients with known arrhythmias or concurrent QT‑prolonging drugs. - Concurrent fluoroquinolone use: avoid duplication of therapy. - Pregnancy and lactation: use only if potential benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Co‑administration with other QT‑prolonging agents (e.g., quinidine, macrolide antibiotics): may increase risk of torsades de pointes. - Concurrent use with warfarin: may enhance anticoagulant effect and increase bleeding risk. - Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs): may raise the likelihood of central nervous system adverse events.

Moderate Interactions (Monitor Closely): - Corticosteroids: may increase risk of tendon rupture. - Theophylline: moxifloxacin can raise plasma theophylline concentrations. - Antacids containing aluminum or magnesium: may affect systemic exposure when given intravenously; monitor for reduced efficacy.